BioSpace News Archive

Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a global leader in photonics-based health monitoring and communications solutions, today announced that it has developed what it believes to be the world’s first micro-transfer-printed (mTP) silicon-photonics-based laser for commercial applications.

Biomea Fusion, Inc. presented “Oral long-acting menin inhibitor normalizes type 2 diabetes in two rat models” at the European Association for the Study of Diabetes Annual Meeting (EASD).

Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—released updated recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis.

Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization, announced the addition of a 12,000 ft² solid-state characterization laboratory.

The Alzheimer’s Drug Discovery Foundation has named Miranda E. Orr, PhD, Assistant Professor of Gerontology and Geriatric Medicine at the Wake Forest University School of Medicine, as the recipient of the 2022 Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Development.

The latest market analysis report published by Reports and Data, titled ‘Global Sialorrhea Market – Forecast to 2030,’ thoroughly examines the Sialorrhea industry to provide essential data & information for the targeted readers.

Efemoral Medical announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Institutes of Health.

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30 a.m. ET.

PepGen Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced the appointment of Habib Joseph Dable to its Board of Directors.